ADMA Biologics Inc (ADMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has a cash flow conversion efficiency ratio of 0.149x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($58.25 Million) by net assets ($390.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADMA Biologics Inc balance sheet quality to measure how much of total assets are equity-financed.
ADMA Biologics Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ADMA Biologics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ADMA Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADMA Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intapp Inc
NASDAQ:INTA
|
0.028x |
|
Newell Rubbermaid Inc.
NASDAQ:NWL
|
0.067x |
|
Homeco Daily Needs REIT
AU:HDN
|
0.020x |
|
First Commonwealth Financial
NYSE:FCF
|
0.032x |
|
Stock Yards Bancorp Inc
NASDAQ:SYBT
|
0.051x |
|
Suzhou Douson Drilling & Production Equipment Co Ltd
SHG:603800
|
-0.045x |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
-0.013x |
|
Novocure Ltd
NASDAQ:NVCR
|
-0.041x |
Annual Cash Flow Conversion Efficiency for ADMA Biologics Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of ADMA Biologics Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see ADMA Biologics Inc (ADMA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $477.32 Million | $50.40 Million | 0.106x | -68.95% |
| 2024-12-31 | $349.02 Million | $118.67 Million | 0.340x | +422.41% |
| 2023-12-31 | $135.21 Million | $8.80 Million | 0.065x | +116.62% |
| 2022-12-31 | $151.97 Million | $-59.51 Million | -0.392x | +50.81% |
| 2021-12-31 | $141.17 Million | $-112.37 Million | -0.796x | +31.14% |
| 2020-12-31 | $88.25 Million | $-102.00 Million | -1.156x | +60.27% |
| 2019-12-31 | $26.19 Million | $-76.19 Million | -2.909x | +8.25% |
| 2018-12-31 | $19.77 Million | $-62.68 Million | -3.170x | -243.07% |
| 2017-12-31 | $40.33 Million | $-37.27 Million | -0.924x | -122.55% |
| 2016-12-31 | $-4.46 Million | $-18.27 Million | 4.099x | +121.82% |
| 2015-12-31 | $820.97K | $-15.42 Million | -18.781x | -667.40% |
| 2014-12-31 | $6.01 Million | $-14.70 Million | -2.447x | -384.94% |
| 2013-12-31 | $21.57 Million | $-10.89 Million | -0.505x | +31.11% |
| 2012-12-31 | $9.42 Million | $-6.90 Million | -0.733x | +92.99% |
| 2011-12-31 | $2.77K | $-29.00K | -10.458x | -118.39% |
| 2010-12-31 | $-346.00 | $-19.68K | 56.867x | -- |
| 2009-12-31 | $0.00 | $-24.46 Million | x | -- |
| 2008-12-31 | $0.00 | $-19.00 Million | x | -- |
| 2007-12-31 | $0.00 | $-23.61 Million | x | -- |
| 2006-12-31 | $0.00 | $-23.61 Million | x | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more